
Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
Income Statement | ||||||
Revenue | $4.5B | $5.3B | $5.7B | $1.3B | $1.4B | |
Gross Profit | $3.7B | $4.2B | $4.5B | $1B | $1.1B | |
Operating Income | $1.5B | $1.5B | $1.6B | $356.7M | $353.3M | |
EBITDA | $1.7B | $1.6B | $1.8B | $297.2M | $483.7M | |
Diluted EPS | $2.44 | $2.30 | $6.97 | $0.61 | $0.65 |
Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | $3.1B | $3.2B | $3.1B | $4B | $6.3B | |
Total Assets | $7.2B | $8.5B | $8.3B | $9.4B | $13.1B | |
Current Liabilities | $893.9M | $1B | $1B | $1.2B | $1.5B | |
Total Liabilities | $2.7B | $2.7B | $2.5B | $2.6B | $3B | |
Total Equity | $4.6B | $5.8B | $5.8B | $6.7B | $10.1B | |
Total Debt | $595M | $595.7M | $596.3M | $597M | $597.7M |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
Cash Flow Statement | ||||||
Cash Flow Operations | $1.2B | $895.8M | $542.3M | $136.6M | -$127.5M | |
Cash From Investing | $252.3M | $173.8M | $2.3B | $14.1M | -$576.7M | |
Cash From Financing | -$1.6B | -$711M | -$983M | -$413.2M | $28.6M | |
Free Cash Flow | $953.4M | $629.5M | $259.9M | $48.3M | -$181.9M |
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
In the current month, EW has received 10 Buy ratings 17 Hold ratings, and 1 Sell ratings. The EW average analyst price target in the past 3 months is $80.42.
According to analysts, the consensus estimate is that Edwards Lifesciences share price will rise to $80.42 per share over the next 12 months.
Analysts are divided on their view about Edwards Lifesciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Edwards Lifesciences is a Sell and believe this share price will drop from its current level to $61.00.
The price target for Edwards Lifesciences over the next 1-year time period is forecast to be $80.42 according to 28 Wall Street analysts, 10 of them rate the stock a Buy, 1 rates the stock a Sell, and 17 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Edwards Lifesciences is a Hold. 17 of 28 analysts rate the stock a Hold at this time.
You can purchase shares of Edwards Lifesciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Edwards Lifesciences shares.
Edwards Lifesciences was last trading at $68.51 per share. This represents the most recent stock quote for Edwards Lifesciences. Yesterday, Edwards Lifesciences closed at $68.39 per share.
In order to purchase Edwards Lifesciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
For the last few years, earnings growth from the tech…
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
For many years, Walmart (NYSE:WMT) has been the world’s largest…
Market Cap: $3.3T
P/E Ratio: 36x
Market Cap: $2.8T
P/E Ratio: 32x
Market Cap: $2.7T
P/E Ratio: 37x
Guardant Health [GH] is up 1.1% over the past day.
Teradyne [TER] is down 0.36% over the past day.
Limbach Holdings [LMB] is down 4.39% over the past day.